As the pool of approved therapies continues to (hopefully) expand, the clinical and diagnostic testing communities need to do a better job at ensuring the right patients move through this journey more quickly – and accurately – to improve their health and prognosis.
While advancements in diagnostics are promising, the need remains for healthcare professionals to take the lead on proactive conversations with patients and their loved ones about the early signs and symptoms of Alzheimer’s disease.
Break down the silos. Take control of your provider data.
Early diagnosis through blood tests buys invaluable time – for patients and their families to plan, seek support, make informed decisions about their difficult care journey and, perhaps most importantly, be together.
Wearable technology seems to offer great potential for early detection and management of agitation experienced by people with communication-impaired neurological disorders, allowing caregivers to provide personalized interventions that could significantly improve patients’ lives.
In-home hospice care, which gives them ample opportunities to engage with family and friends in the comfort of their own homes, allows providers to give dementia patients the daily contact they deserve.
Many women going through menopause suffer brain fog, but some may be worried about a more serious cognitive condition like dementia. Because of this, Midi Health and Neurotrack partnered to offer a cognitive assessment to patients.
The home care industry is booming. As Baby Boomers age and more families seek in-home solutions for loved ones, demand for home care services is at an all-time high.
GUIDE — Guiding an Improved Dementia Experience — is the new dementia care model from the CMS and the CMMI (Centers for Medicare and Medicaid Innovation) for beneficiaries covered by traditional fee-for-service (FFS) Medicare and their caregivers. It represents an incremental step forward in managing neurodegenerative diseases effectively.
Dementia patients require a balanced blend of supportive devices, effective medications such as cholinesterase inhibitors and holistic understanding to truly enjoy the best possible quality of life.
We may not fully understand the link between Covid-19 and Alzheimer’s, but we already have the scientific research and tools to address people’s fears, support their cognitive health journey, and reverse the increase of Alzheimer’s.
A budget estimate attached to proposed legislation in Montana raises questions about whether the state's cash-strapped communities will have the capacity to care for patients with Alzheimer’s disease, other types of dementia or traumatic brain injuries by July 2025, when involuntary commitments would cease under the plan.
Healthcare is drowning in chaos—from scattered data to burnout-inducing tasks. Discover how smarter workflows and real-time insights can rescue care teams and transform patient outcomes.
Reducing hospitalizations for frail elderly members is a major challenge for Medicare Advantage payers and providers. The key to avoiding any hospitalization is to detect and address a change in condition before it worsens. Ceresti Co-founder and CEO Dirk Soenksen talks about how his company is addressing these needs.
Ideally, novel therapeutics will be introduced in combination with lifestyle interventions that are going to need to be personalized to each individual, and anchored in reliable, longitudinal metrics to enable modifications as needed.
Too many of us and our families have been affected by dementia in one form or another. October is recognized by patients, advocates and the medical community as Lewy Body Dementia Awareness month, and perhaps this year it will mark new hope for those suffering from this disease.
There is a dearth of professionals with licenses and training to provide care for seniors’ mental and behavioral health challenges — such as Alzheimer's and other dementias, anxiety and depression. Seattle-based Rippl Care is seeking to change this. The startup just closed a $32 million seed funding round led by ARCH Venture Partners and General Catalyst.
Eli Lilly is among the new investors joining the Series B round of Arkuda Therapeutics, a biotech developing a drug to treat a rare, inherited form of dementia. If the biotech’s approach works, it could also have applications in other neurodegenerative conditions such as Alzheimer’s and Parkinson’s.